RT @keisuke4713: 「仮説の帰結と考察」 SARS-CoV-2 spike蛋白💉はDNA損傷を誘発、炎症⬆、発癌経路⬆、免疫応答の微調整を妨害risk これら調節不全機序とsignal伝達経路は、殆どの癌の根底 特に懸念:一部抗癌剤がコロナ💉無効にする結果 リン…
「仮説の帰結と考察」 SARS-CoV-2 spike蛋白💉はDNA損傷を誘発、炎症⬆、発癌経路⬆、免疫応答の微調整を妨害risk これら調節不全機序とsignal伝達経路は、殆どの癌の根底 特に懸念:一部抗癌剤がコロナ💉無効にする結果 リンパ腫CD20標的療法は💉のde novo抗体応答を除去 https://t.co/5jAYhiWEfQ
RT @tanaya_shree: We are recommending vaccinating/boosting before treatment in all who can wait a little before starting anti-CD20-based tr…
CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Preestablished Immunity https://t.co/MqMro8x6C2
The authors of "CD20-Targeted Therapy Ablates De Novo Antibody Res…" (https://t.co/vmAQLqSTe1) included RRIDs in their paper! Thank you for making your #methodsmatter. #OpenScience
#ICYMI: CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Pre-Established Immunity by @tanaya_shree et al. https://t.co/3Q0BudXZwH @StanfordMed #COVID19 #lymsm #immunotherapy https://t.co/KVZOtMpvS4
RT @BCD_AACR: From the March Issue: CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Pre-Established Immun…
From the March Issue: CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Pre-Established Immunity by @tanaya_shree et al. https://t.co/bqTRqPwNaN @StanfordMed #COVID19 #lymsm #immunotherapy https://t.co/oVQ5TyTZsr
@KathMLee1 @rodante313 I found Stanfords response to this study troublesome. Thanks for looking, it is appreciated. https://t.co/iPU9hMxID0
RT @Nachtzuster2: 31/1/22 - volgens onderzoekers van Stanford Medicine: “Mensen die zijn behandeld met rituximab, een veelgebruikt medicijn…
RT @Nachtzuster2: 31/1/22 - volgens onderzoekers van Stanford Medicine: “Mensen die zijn behandeld met rituximab, een veelgebruikt medicijn…
RT @Nachtzuster2: 31/1/22 - volgens onderzoekers van Stanford Medicine: “Mensen die zijn behandeld met rituximab, een veelgebruikt medicijn…
Ben nog ff de draad kwijt maar zal moeten lezen waar ik hem weer opkam pakken..
RT @Dover63A: Vaccinons les plus fragiles en priorité ? Il ne reste que les effets indésirables... "Aucun des 31 patients qui avaient re…
RT @Dover63A: Vaccinons les plus fragiles en priorité ? Il ne reste que les effets indésirables... "Aucun des 31 patients qui avaient re…
RT @Nachtzuster2: 31/1/22 - volgens onderzoekers van Stanford Medicine: “Mensen die zijn behandeld met rituximab, een veelgebruikt medicijn…
RT @Dover63A: Vaccinons les plus fragiles en priorité ? Il ne reste que les effets indésirables... "Aucun des 31 patients qui avaient re…
RT @Dover63A: Vaccinons les plus fragiles en priorité ? Il ne reste que les effets indésirables... "Aucun des 31 patients qui avaient re…
RT @Nachtzuster2: 31/1/22 - volgens onderzoekers van Stanford Medicine: “Mensen die zijn behandeld met rituximab, een veelgebruikt medicijn…
RT @Dover63A: Vaccinons les plus fragiles en priorité ? Il ne reste que les effets indésirables... "Aucun des 31 patients qui avaient re…
RT @Dover63A: Vaccinons les plus fragiles en priorité ? Il ne reste que les effets indésirables... "Aucun des 31 patients qui avaient re…
RT @Dover63A: Vaccinons les plus fragiles en priorité ? Il ne reste que les effets indésirables... "Aucun des 31 patients qui avaient re…
RT @Nachtzuster2: 31/1/22 - volgens onderzoekers van Stanford Medicine: “Mensen die zijn behandeld met rituximab, een veelgebruikt medicijn…
RT @Dover63A: Vaccinons les plus fragiles en priorité ? Il ne reste que les effets indésirables... "Aucun des 31 patients qui avaient re…
RT @Dover63A: Vaccinons les plus fragiles en priorité ? Il ne reste que les effets indésirables... "Aucun des 31 patients qui avaient re…
RT @Nachtzuster2: 31/1/22 - volgens onderzoekers van Stanford Medicine: “Mensen die zijn behandeld met rituximab, een veelgebruikt medicijn…
RT @Dover63A: Vaccinons les plus fragiles en priorité ? Il ne reste que les effets indésirables... "Aucun des 31 patients qui avaient re…
RT @Dover63A: Vaccinons les plus fragiles en priorité ? Il ne reste que les effets indésirables... "Aucun des 31 patients qui avaient re…
RT @Dover63A: Vaccinons les plus fragiles en priorité ? Il ne reste que les effets indésirables... "Aucun des 31 patients qui avaient re…
RT @Dover63A: Vaccinons les plus fragiles en priorité ? Il ne reste que les effets indésirables... "Aucun des 31 patients qui avaient re…
RT @Dover63A: Vaccinons les plus fragiles en priorité ? Il ne reste que les effets indésirables... "Aucun des 31 patients qui avaient re…
RT @Dover63A: Vaccinons les plus fragiles en priorité ? Il ne reste que les effets indésirables... "Aucun des 31 patients qui avaient re…
RT @Dover63A: Vaccinons les plus fragiles en priorité ? Il ne reste que les effets indésirables... "Aucun des 31 patients qui avaient re…
RT @Dover63A: Vaccinons les plus fragiles en priorité ? Il ne reste que les effets indésirables... "Aucun des 31 patients qui avaient re…
RT @Dover63A: Vaccinons les plus fragiles en priorité ? Il ne reste que les effets indésirables... "Aucun des 31 patients qui avaient re…
RT @Dover63A: Vaccinons les plus fragiles en priorité ? Il ne reste que les effets indésirables... "Aucun des 31 patients qui avaient re…
RT @Dover63A: Vaccinons les plus fragiles en priorité ? Il ne reste que les effets indésirables... "Aucun des 31 patients qui avaient re…
RT @Dover63A: Vaccinons les plus fragiles en priorité ? Il ne reste que les effets indésirables... "Aucun des 31 patients qui avaient re…
RT @Dover63A: Vaccinons les plus fragiles en priorité ? Il ne reste que les effets indésirables... "Aucun des 31 patients qui avaient re…
RT @Dover63A: Vaccinons les plus fragiles en priorité ? Il ne reste que les effets indésirables... "Aucun des 31 patients qui avaient re…
RT @Dover63A: Vaccinons les plus fragiles en priorité ? Il ne reste que les effets indésirables... "Aucun des 31 patients qui avaient re…
RT @Dover63A: Vaccinons les plus fragiles en priorité ? Il ne reste que les effets indésirables... "Aucun des 31 patients qui avaient re…
RT @Dover63A: Vaccinons les plus fragiles en priorité ? Il ne reste que les effets indésirables... "Aucun des 31 patients qui avaient re…
RT @Dover63A: Vaccinons les plus fragiles en priorité ? Il ne reste que les effets indésirables... "Aucun des 31 patients qui avaient re…
RT @Dover63A: Vaccinons les plus fragiles en priorité ? Il ne reste que les effets indésirables... "Aucun des 31 patients qui avaient re…
RT @Dover63A: Vaccinons les plus fragiles en priorité ? Il ne reste que les effets indésirables... "Aucun des 31 patients qui avaient re…
RT @Dover63A: Vaccinons les plus fragiles en priorité ? Il ne reste que les effets indésirables... "Aucun des 31 patients qui avaient re…
RT @Dover63A: Vaccinons les plus fragiles en priorité ? Il ne reste que les effets indésirables... "Aucun des 31 patients qui avaient re…
RT @Dover63A: Vaccinons les plus fragiles en priorité ? Il ne reste que les effets indésirables... "Aucun des 31 patients qui avaient re…
RT @Dover63A: Vaccinons les plus fragiles en priorité ? Il ne reste que les effets indésirables... "Aucun des 31 patients qui avaient re…
RT @Dover63A: Vaccinons les plus fragiles en priorité ? Il ne reste que les effets indésirables... "Aucun des 31 patients qui avaient re…
RT @Dover63A: Vaccinons les plus fragiles en priorité ? Il ne reste que les effets indésirables... "Aucun des 31 patients qui avaient re…
Vaccinons les plus fragiles en priorité ? Il ne reste que les effets indésirables... "Aucun des 31 patients qui avaient reçu un traitement anti-CD20 dans les 6 mois précédant la vaccination n'a développé d'anticorps bloquants." https://t.co/xAyaL2RX9P
RT @BCD_AACR: CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Preestablished Immunity, by @tanaya_shree,…
RT @BCD_AACR: CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Preestablished Immunity, by @tanaya_shree,…
RT @BCD_AACR: CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Preestablished Immunity, by @tanaya_shree,…
RT @BCD_AACR: CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Preestablished Immunity, by @tanaya_shree,…
CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Preestablished Immunity, by @tanaya_shree, Levy, et al. @AshAlizadeh https://t.co/LPT3rxdhb3 #AACRCOVIDReport https://t.co/dNcERKsBjz
CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Preestablished Immunity. https://t.co/ilJ9YD6xiq #AACRCOVIDReport
CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Pre-Established Immunity https://t.co/vMs5c77WjO vaccination in immunecompromised issued December 2021
RT @tobyeyre82: CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Pre-Established Immunity https://t.co/0MS…
RT @SSBMT: Patients who initiated anti-CD20 treatment shortly after achieving a vaccine-induced antibody response tended to retain that res…
Patients who initiated anti-CD20 treatment shortly after achieving a vaccine-induced antibody response tended to retain that response during treatment, suggesting a policy of immunizing prior to treatment whenever possible. #COVID19 #ssbmt https://t.co/Ow
RT @GuillaumeDachy: A question we've been asking ourself almost every day... Yes we should vaccinate our patients prior to anti CD 20 thera…
A question we've been asking ourself almost every day... Yes we should vaccinate our patients prior to anti CD 20 therapies... https://t.co/UxRpJPpYY4
RT @tobyeyre82: CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Pre-Established Immunity https://t.co/0MS…
RT @graham74GC: Really important data suggesting we should be COVID vaccinating patient prior to anti-CD20 based therapies.
CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Pre-Established Immunity [Jan 6, 2022] @tanaya_shree et al. @BCD_AACR https://t.co/DO5NYrWqL0 #COVID19Vaccine #COVID19nCancer #IDonc #lymsm #COVID19 HT @tobyeyre82
RT @graham74GC: Really important data suggesting we should be COVID vaccinating patient prior to anti-CD20 based therapies.
RT @graham74GC: Really important data suggesting we should be COVID vaccinating patient prior to anti-CD20 based therapies.
RT @tobyeyre82: CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Pre-Established Immunity https://t.co/0MS…
RT @tobyeyre82: CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Pre-Established Immunity https://t.co/0MS…
RT @graham74GC: Really important data suggesting we should be COVID vaccinating patient prior to anti-CD20 based therapies.
RT @graham74GC: Really important data suggesting we should be COVID vaccinating patient prior to anti-CD20 based therapies.
RT @graham74GC: Really important data suggesting we should be COVID vaccinating patient prior to anti-CD20 based therapies.
@JoshuaHillMD how would you interpret these data in the context of CD19 CAR-T where most pt. are B-cell aplastic at baseline? Still room for a T-cell response?
RT @tobyeyre82: CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Pre-Established Immunity https://t.co/0MS…
RT @graham74GC: Really important data suggesting we should be COVID vaccinating patient prior to anti-CD20 based therapies.
RT @tobyeyre82: CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Pre-Established Immunity https://t.co/0MS…
RT @tobyeyre82: CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Pre-Established Immunity https://t.co/0MS…
RT @graham74GC: Really important data suggesting we should be COVID vaccinating patient prior to anti-CD20 based therapies.
RT @graham74GC: Really important data suggesting we should be COVID vaccinating patient prior to anti-CD20 based therapies.
RT @graham74GC: Really important data suggesting we should be COVID vaccinating patient prior to anti-CD20 based therapies.
RT @graham74GC: Really important data suggesting we should be COVID vaccinating patient prior to anti-CD20 based therapies.
RT @tobyeyre82: CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Pre-Established Immunity https://t.co/0MS…
RT @graham74GC: Really important data suggesting we should be COVID vaccinating patient prior to anti-CD20 based therapies.
RT @tobyeyre82: CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Pre-Established Immunity https://t.co/0MS…
RT @tobyeyre82: CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Pre-Established Immunity https://t.co/0MS…
RT @tobyeyre82: CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Pre-Established Immunity https://t.co/0MS…
RT @tobyeyre82: CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Pre-Established Immunity https://t.co/0MS…
RT @graham74GC: Really important data suggesting we should be COVID vaccinating patient prior to anti-CD20 based therapies.
RT @graham74GC: Really important data suggesting we should be COVID vaccinating patient prior to anti-CD20 based therapies.